Amarin to Report Third Quarter 2026 Financial Results and Host Conference Call on October 28, 2026GlobeNewsWire · 3 days ago
Head-To-Head Survey: Amarin (NASDAQ:AMRN) and SCYNEXIS (NASDAQ:SCYX)Defense World · Sep 30, 2026
Analyzing Amarin (NASDAQ:AMRN) & Elanco Animal Health (NYSE:ELAN)Defense World · Sep 19, 2026
Is Amarin (AMRN) Stock Outpacing Its Medical Peers This Year?Zacks Investment Research · Sep 9, 2026
Amarin Highlights New REDUCE-IT® and Mechanistic Data Presented at European Society of Cardiology (ESC) Congress 2026GlobeNewsWire · Aug 31, 2026
New REDUCE-IT® Legacy Analysis Presented at European Society of Cardiology (ESC) Congress 2026 Suggests Persistent Cardiovascular Benefit Following Icosapent Ethyl Treatment Cessation in Adherent PatientsGlobeNewsWire · Aug 28, 2026Amarin Corporation plc is a pharmaceutical firm dedicated to the research, development, and commercialization of therapeutic solutions for cardiovascular diseases. Its operations span several international regions, including the United States, Germany, Canada, Lebanon, and the United Arab Emirates. The company's flagship product is VASCEPA, an omega-3 fatty acid formulation available by prescription only.
| Date | Est. | Actual | |
|---|---|---|---|
| Jul 29, 2026 | -$0.01 | -$0.02 | Miss |
| Apr 29, 2026 | $0.01 | -$0.09 | Miss |
| Feb 25, 2026 | $0.07 | $0.01 | Miss |
| Oct 29, 2025 | $0.08 | $0.01 | Miss |
| Jul 30, 2025 | -$0.66 | -$0.03 | Beat |
| May 7, 2025 | -$1.12 | -$0.04 | Beat |